About

OKYO Pharma Ltd. (LSE:OKYO, NASDAQ:OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is developing a lipidated chemerin-peptide drug candidate OK-101, designed to target a key ocular receptor controlling inflammation and ocular pain. The drug, developed by a unique proprietary membrane anchored technology, is designed to increase agonist potency and ocular residence time.